The latest news, announcements and press releases from Iktos.
Pierre Fabre Laboratories and Iktos, a global leader in Artificial Intelligence (AI) and Robotics on drug discovery, today announced an integrated drug discovery collaboration to identify and develop novel small-molecule drug candidates in oncology. This initiative reflects both companies’ commitment to advancing oncology research by integrating complementary strengths across computational design, medicinal chemistry, biology, medical science and preclinical development.
Under the terms of the agreement, Iktos will leverage its AI-driven generative design platform to accelerate the discovery of optimized small-molecule candidates against an undisclosed oncology target. Pierre Fabre Laboratories will contribute its extensive knowledge in oncology research and preclinical development to guide the selection, evaluation, and progression of candidate molecules.
Cinisello Balsamo,18th June 2024 – Italfarmaco SpA (ITF), a private global pharmaceutical company, and Iktos, a company specializing in Artificial Intelligence (AI) for new drug design, today announced a collaboration to develop next generation HDAC inhibitors for a variety of non-oncological diseases, including diseases affecting the central nervous system.
The new partnership between Elsevier and Iktos is set to accelerate small molecule development in pharma. See what the two main architects have to say.
This is the News section of the company profile page for Iktos on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
